A groundbreaking discovery in the fight against dementia has shed light on a long-standing medical mystery: why do cancer survivors have a significantly lower risk of developing cognitive diseases later in life? This intriguing connection between cancer and dementia has puzzled scientists for decades, but recent research may have unlocked the secret.
Scientists at Huazhong University of Science and Technology in China have identified a key protein, cystatin C, which is released by cancer cells during tumor growth. This protein has the unique ability to cross the blood-brain barrier, a protective mechanism that typically blocks harmful substances from entering the brain. Once inside, cystatin C triggers a reaction that breaks down the abnormal protein clumps, known as amyloid plaques, which are strongly linked to dementia.
The research, published in the prestigious journal Cell, was based on animal studies, and further investigations are needed to confirm if the same process occurs in humans. However, this discovery could be a game-changer in the search for effective dementia treatments.
Elio Riboli, a renowned professor of cancer epidemiology and prevention at Imperial College London, believes this research is a significant step forward. "It's very intriguing and might explain one of the mechanisms behind the lower dementia risk observed in cancer survivors," he says. "It opens up the possibility of developing new drugs that target this protein and potentially prevent dementia."
Dementia is a devastating condition affecting over 900,000 people in the UK alone, and it claims more lives annually than cancer or heart disease. Current drug treatments, such as cholinesterase inhibitors, can provide some relief but are not a cure. Newer drugs like lecanemab and donanemab have shown promise in slowing the disease's progression, but their limitations and potential side effects have prevented their widespread use.
Understanding why cancer might protect some individuals from dementia could be crucial in developing more effective medications. While cancer survivors, especially those who had cancer as children, often have shorter lifespans due to the toxic effects of treatments, studies have consistently shown that cancer reduces the risk of dementia, even when accounting for these factors.
The latest research involved transplanting human lung, prostate, and bowel cancer samples into mice genetically predisposed to dementia. Remarkably, none of the mice developed the brain plaques associated with the condition. The research team then spent years identifying the specific protein responsible for this protective effect, eventually pinpointing cystatin C.
During subsequent tests, the researchers found that cystatin C binds to brain plaques, activating immune cells in the brain to attack and break down the plaques. Mice with dementia-like deposits injected with cystatin C showed improvements in memory and learning.
Cystatin C is not the only cancer-related protein showing promise in dementia prevention. Scientists at Bristol University are investigating the role of PIN1, a protein released by cancer cells to stimulate tumor growth. Their research suggests that the more active PIN1 is in driving cancer growth, the more protected the brain is against cognitive failure linked to amyloid plaques and tau protein accumulation, another dementia-related protein.
The Bristol team is also exploring the potential role of PI3K, an enzyme that is highly active in cancer, aiding malignant cell proliferation and disease spread. Interestingly, in dementia patients without a history of cancer, PI3K activity is significantly reduced. It is believed that cancer stimulates PI3K activity, which then protects the brain against dementia by preventing deposit formation.
Additionally, there is evidence suggesting that individuals who develop dementia are less likely to get cancer. A 2017 study in Taiwan found that Alzheimer's patients were nearly 20% less likely to develop any form of cancer, with other studies reporting a reduction in cancer risk as high as 60%. The theory behind this is that the destruction of brain cells in dementia suppresses the enzymes that promote cancer growth.
Professor Riboli cautions that the solution may not be as straightforward as targeting a single cancer-secreted protein. "Cystatin C is likely not the only protein involved, and it may not even be the most significant one," he says. "However, this new study highlights the powerful protective effect that cancer proteins may have against the formation of amyloid plaques."
This research opens up a new avenue for exploring the complex relationship between cancer and dementia and offers hope for developing more effective treatments and prevention strategies.
Join the debate: Should we explore the potential of cancer-related discoveries to reshape our approach to dementia treatment and prevention? Share your thoughts in the comments below!
